Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 25 November 2020 | By Renee Matthews
A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA).
New approvals Zokinvy okayed as first therapy for rare premature aging diseases Eiger BioPharmaceuticals’ Zokinvy (lonafarnib capsules) has been approved for reducing the risk of death from Hutchinson-Gilford progeria syndrome and treating certain processing-deficient progeroid laminopathies in patients aged 1 year or older.
The rare genetic diseases cause premature aging and death. Accumulation of defective progerin or progerin-like protein in cells accelerates cardiovascular disease in these patients, and most die from heart failure, heart attack, or stroke before they reach the age of 15 years. Treatment options until now have been limited to supportive care and therapies that mitigate disease-related complications.
Zokinvy acts by blocking the build-up of defective progerin or progerin-like protein. Its effectiveness in treating Hutchinson-Gilford progeria syndrome was demonstrated in two single-arm trials in 62 patients, who were compared with matched, untreated patients. The lifespan of patients receiving Zokinvy increased by an average of 3 months in the first 3 years of therapy and of 2.5 years over 11 years follow-up.
The application was granted priority review designation. The therapy received orphan drug and breakthrough therapy designations, and the manufacturer received a rare pediatric disease priority review voucher.
Oxlumo gets go-ahead as first drug for rare genetic kidney-related disorder Alnylam’s Oxlumo (lumasiran) has been approved as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder that causes recurrent kidney stones and progressive loss of kidney function.
“The approval of Oxlumo represents a great triumph of community involvement to address a rare disease. It is a result of input from patients, treating physicians, experts and sponsors at a patient-focused drug development meeting and through other collaborative efforts,” said Norman Stockbridge, MD, PhD, director of the Division of Cardiology and Nephrology in the FDA’s Center for Drug Evaluation and Research.
Patients with PH1 produce an excess of oxalate that combines with calcium, causing kidney stones and calcium deposits in the kidneys. In addition to kidney damage and possible failure, the build-up can also damage organs such as the heart, bones, and eyes. Oxlumo’s mechanism of action involves targeting and decreasing the production of oxalate.
The therapy was evaluated in two studies in patients with PH1 whose ages ranged from 4 months to 61 years. In the randomized, placebo-controlled ILLUMINATE-A study in patients aged 6 years or older, 26 patients received a monthly injection of Oxlumo, followed by a maintenance dose every 3 months, and 13 patients received placebo injections. Those receiving the study drug showed an average 65% reduction of oxalate in the urine, compared with an average 12% reduction in controls. After 6 months, 52% of patients treated with Oxlumo attained a normal 24-hour urinary oxalate level. None of the placebo patients attained normal level.
All 16 patients in the open-label ILLUMINATE-B study were younger than 6 years and all received Oxlumo. Investigators used a different measure for urinary oxalate levels than that used in the first study. By the sixth month, there was an average 71% decrease in urinary oxalate among the patients.
Oxlumo received orphan drug designation, and the application was granted breakthrough therapy designation. The manufacturer received a rare pediatric disease priority review voucher.
New indications Xofluza picks up expanded indication for postexposure prevention Genentech’s Xofluza (baloxavir marboxil) has received an expanded indication for postexposure prevention of influenza (flu) for patients aged 12 years or older after contact with a person with flu.
The drug also has a new formulation – it is now available in granular form for mixing with water in additional to its original tablet form in its 2018 approval as a treatment for uncomplicated flu in patients aged 12 years or older.
Xofluza’s safety and efficacy for postexposure prevention was supported by findings from a double-blind, controlled trial of 607 patients aged 12 years or older and randomized to receive Xofluza or placebo after exposure to a person with flu.
One percent of patients receiving Xofluza were infected with the flu virus and presented with fever and at least one respiratory symptom in the first 10 days after exposure, compared with 13% of those who received placebo.
Debra Birnkrant, MD, director of the Division of Antiviral Products in the FDA’s Center for Drug Evaluation and Research, noted in a press release that the expanded indication is an important option for patients and providers in the upcoming flu season, which will be unprecedented because of the ongoing COVID-19 pandemic.
Tags: FDA, US
Regulatory Focus newsletters
All the biggest regulatory news and happenings.